DAVITA INC. Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount
DAVITA INC. (DVA) reported Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount of $69.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense · last filed 2026-02-11
- DAVITA INC. effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2025 was $69.03M, a 4.30% increase from fiscal 2024.
- DAVITA INC. effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2024 was $66.19M, a 19.80% increase from fiscal 2023.
- DAVITA INC. effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2023 was $55.24M.
| Period end | Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount 12 month |
|---|---|
| 2025-12-31 | $69.03M 10-K · filed 2026-02-11 |
| 2024-12-31 | $66.19M 10-K · filed 2026-02-11 |
| 2023-12-31 | $55.24M 10-K · filed 2026-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |